Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO
IPO Overview
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Generate Biomedicines states that its AI-enabled Generate Platform is a tight and fully-integrated loop （design–build–test–learn） aimed to create proprietary, therapeutically relevant data and differentiated molecular solutions. The company claims that its therapeutic potential has been demonstrated by successfully progressing three computationally engineered proteins into human clinical testing, the most advanced of which is GB-0895, an investigational long-acting anti-thymic stromal lymphopoietin （“TSLP”） monoclonal antibody, which is enrolling patients in pivotal Phase 3 clinical trials for severe asthma.
The Somerville, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol GENB. Generate Biomedicines filed confidentially on December 23, 2025. Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald are the joint bookrunners on the deal.
About the Company
We are a blank check company incorporated on July 18, 2025 as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any discussions, directly or indirectly, with any business combination target regarding an initial business combination with our company. Our efforts to identify a prospective target business will not be limited to a particular industry, sector or geographic region, although we expect to focus on a target in an industry where we believe our management team’s and our and their affiliates’ expertise will provide us with a competitive advantage. Through our management team, we expect to have differentiated access to deal flow extending beyond the U.S., with a particular focus on Europe, through （a） our global network and extensive partner ecosystem, （b） trusted relationships with entrepreneurs, executives and financials sponsors, and （c） deep sector expertise combined with proven execution insight. However, we currently expect to favor potential target companies that possess certain attributes, including, but not limited to: cross-border and international operations, non-U.S. market leaders with strong appeal to U.S.-based investors, positive long term growth prospects, competitive advantages, consolidation opportunities, recurring revenue or the potential for recurring revenue, opportunities for operational improvement and attractive margins or the potential for attractive margins.